

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----  
FORM 8-K  
-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  
May 3, 2005

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah 87-0500306

(State or other jurisdiction of (IRS Employer Identification  
incorporation) Number)

3838 West Parkway Boulevard  
Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On May 3, 2005, USANA Health Sciences, Inc. issued a press release  
announcing that its board of directors has authorized an additional \$30 million  
for share repurchases of its outstanding common stock. The release also  
announced that share repurchases will be made from time-to-time, in the open  
market, through block trades or otherwise, and will be funded with internally  
generated cash. A copy of the press release is furnished herewith as Exhibit

99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website, [www.usanahealthsciences.com](http://www.usanahealthsciences.com), under the "investors" link.

Item 9.01 Financial Statements and Exhibits (furnished herewith)

(c) Exhibits

Exhibit 99.1 Press release issued by USANA Health Sciences, Inc. dated May 3, 2005

2

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller

\_\_\_\_\_

Gilbert A. Fuller, Chief Financial Officer

Date: May 5, 2005

3

## Exhibit 99.1

### USANA Board Authorizes Additional \$30 Million for Share Repurchases

SALT LAKE CITY--(BUSINESS WIRE)--May 3, 2005--USANA Health Sciences Inc. (Nasdaq: USNA) today announced that its board of directors has authorized an additional \$30 million for share repurchases of its outstanding common stock.

Repurchases will be made from time to time, in the open market, through block trades or otherwise, and will be funded with internally generated cash. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities, and other factors.

On April 22, 2005, USANA announced that it had increased the amount available for additional share repurchases to \$10 million. Repurchases under that previous authorization have been completed. During 2004, the company repurchased a total of 1.2 million shares for a total investment of \$34.9 million or an average of \$29.02 per share.

USANA had 18,927,128 common shares outstanding as of April 29, 2005.

#### About USANA

USANA develops and manufactures high-quality nutritional and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, the Netherlands, and the United Kingdom. More information on USANA can be found at <http://www.usanahealthsciences.com>.

#### Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, and uncertainties associated with our planned international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

CONTACT: USANA Health Sciences Inc., Salt Lake City  
Riley Timmer, 801-954-7100  
[investor.relations@us.usana.com](mailto:investor.relations@us.usana.com)